Brief: Cleveland Biolabs reports Q4 loss per share $0.11
22/02/2017 21:15
Feb 22 (Reuters) - Cleveland Biolabs Inc CBLI.O
* Cleveland Biolabs reports 2016 financial results and
development progress
* Q4 loss per share $0.11
* Q4 revenue $1.0 million versus $1.3 million
* Cleveland Biolabs - as of Dec 31, cash, cash equivalents,
short-term investments estimated to fund operations for at least
one year beyond filing of form 10-k
Source text for Eikon: ID:nMKW4KfYVa
Further company coverage: CBLI.O
((bangalore.newsroom@thomsonreuters.com;))
Recent news on Statera Biopharma
See all news20/20 Biolabs jumps on Ebola, hantavirus testing plans
Tivic Health Systems rises after deal for late-stage immunotherapy drug
Brief: Tivic Health Acquires Exclusive Worldwide Rights To Phase III TLR5 Agonist
Brief: Statera Biopharma Inc Quarterly Loss Per Share $0.20
Brief: Statera Biopharma Inc - On October 12, 2022, Co Entered A Binding Memorandum Of Understanding (“MoU”) With Holobeam Technologies, Inc